Was the 50 mg tablet really an accident?
The folder that missed its chest-pain endpoint
Late-1980s brief: relax coronary smooth muscle, ease angina.
PDE5 was a rational heart target long before anyone wrote ED on the cover.
Pfizer chemists set out to block phosphodiesterase type 5 so cyclic GMP would linger in vessel walls. Longer cyclic GMP means smoother muscle stays relaxed. On paper that should have opened coronary flow. The candidate that left the bench was coded UK-92,480 - later sildenafil citrate.
Early human work in angina and hypertension was polite and small. Coronary change showed up, then plateaued below what a new heart drug needed. That is a standard kill point. Teams archive the lot, write a decent close-out, and move the next analog forward. This file almost died there.
I still write the distinction in the margin: missed endpoint is not a broken target. Nitric oxide already talks to coronary muscle. The dose-response just never grew into a product. If you want the enzyme map that survived, open the sildenafil note - the hold and the milligram sit there, not in this history.
Readers keep asking whether the heart idea was silly. It was not. It was thin. Thin programs get shelved every year. This one lived because someone read the adverse-event column instead of only the ST-segment column. I would rather teach that reading habit than retell the blue-pill myth for the hundredth time.
Kent chemistry, not a Manhattan launch
Sandwich, Kent, was a workhorse site. Analog after analog, affinity panels, a selectivity screen against the rest of the phosphodiesterase family. UK-92,480 was potent and fairly clean on PDE5. That is ordinary medicinal chemistry, not a press story.
Selectivity is why the later side effect made sense. PDE5 sits in more than one bed. Penile smooth muscle carries a dense share. Coronary muscle carries less. The same tablet can look modest in one circulation and obvious in another. Nobody designed the first protocol around that density map.
I tell residents the code number is an inventory tag, not a brand. Viagra arrived years later. Generic 50 mg tablets arrived after the patent. The molecule did not change its mind in between.
Phosphodiesterase panels were already routine. Choosing PDE5 was a decision. Calling the later erection signal an accident is fine if you mean the organ. It is sloppy if you mean the enzyme.
What the adverse-event log actually logged
Angina visits collected side effects the way every early file does.
Recurrent line: erections a day or two after the dose.
Trial nurses first coded those erections as unrelated nuisance. That is how AE logs work when the primary question is chest pain. Pattern recognition came later, after enough men said the same awkward sentence in follow-up.
Once someone put the pathway on one line, the biology stopped looking random. Arousal releases nitric oxide. Nitric oxide raises cyclic GMP. Cyclic GMP relaxes cavernosal muscle. Blood fills. PDE5 normally chops the signal. Block the chop, and a stimulated erection lasts. No stimulation, almost nothing to amplify. The pill is a hold on the breakdown, not a switch.
That is the pivot I still underline. A failed angina compound might be the first oral ED therapy if you are willing to change the cover of the folder. Dedicated ED trials followed. Questionnaires, diaries, more than one etiology. The chemistry stayed. The claim changed.
Tissue density explains the split personality. Coronary vasodilation stayed modest. Erectile effect was clinically loud in those early cohorts. Same cyclic GMP story, different local enzyme load. I have watched teams discard 'nuisance' AEs that later become the product. This is the example I use when a junior wants to skip the free-text column.
How 50 mg became the first oral ED tablet
ED development needed instruments the angina file never carried. International Index of Erectile Function. Sexual Encounter Profile items on penetration and maintenance. Placebo arms, because first-in-class has no sister pill to beat. Diabetes, nerve-sparing prostatectomy, mixed psychogenic stories - the program had to show the signal was not a healthy-volunteer curiosity.
March 1998: the FDA approved sildenafil citrate as Viagra, the first oral treatment for erectile dysfunction. Recommended start for most men: 50 mg about an hour before activity, once in 24 hours, with room to step to 25 mg or 100 mg. That 50 mg start is still the tablet I write first on a clean ED margin. This site's lock is 25 or 50 - 100 mg is a later step, not the SERP line.
Stimulation dependence was nailed in those packages and never left the class. Later PDE5 tablets inherited the counseling line. If you want the scored rows rather than the origin story, the fasted-clock reviews keep IIEF and SEP honest. If you want the dinner problem, the dinner-timing note is the peer-line I send first.
First-in-class also meant no head-to-head comfort. Placebo was the evidence standard. Follow-on chemistry - tadalafil, vardenafil, avanafil - optimized half-life, food, and daily versus as-needed. They did not rediscover the AE. See the tadalafil note if you are comparing duration, not origin.
Revatio is a different product - do not split diamonds
The cardiovascular hypothesis was pointed at the wrong bed first.
Pulmonary arteries, not coronaries, later paid the original logic back.
Pulmonary arterial hypertension narrows the lung vessels and strains the right heart. PDE5 lives in that bed too. Steady inhibition lowers pulmonary pressure. That is a chronic, scheduled job - not a single pre-activity peak.
Revatio arrived in 2005 as sildenafil 20 mg three times daily, doses about 4-6 hours apart. Same molecule. Different brand, different strength, different supervision, different endpoints. Walk distance and hemodynamics, not IIEF. I will not let a reader split a 50 mg ED tablet and call it Revatio. The products are not interchangeable on a kitchen counter.
Exposure pattern is the practical split. ED wants a peak around a planned hour. PAH wants a flatter day. 20 mg TID is not a 'safer tiny Viagra.' It is another labeled use with its own clinic. If a man on your blotter has both stories, two specialists need to talk. Do not freelance the arithmetic.
I file this under 'full circle, not same carton.' The angina team was directionally right about vasodilation. They were in the wrong circulation. That is a useful teaching line. It is a dangerous shopping line.
What I keep in the margin after the pivot
Late 1980s
Sandwich chemists build PDE5 blockers for angina. One lead is coded UK-92,480.
Early 1990s
Angina and blood-pressure work disappoint. Men keep reporting erections in the AE column.
Mid-1990s
The cover is reprinted. Dedicated ED trials confirm a stimulation-dependent oral effect.
1998
FDA approves sildenafil citrate as Viagra. Usual start: 50 mg about an hour before activity.
2005
Sildenafil is approved as Revatio for PAH - 20 mg TID, a different product and schedule.
Half the story is accident of organ. Half is method: targeted chemistry, an honest AE column, and a company willing to reprint the cover. A less curious team would have boxed the angina miss and gone home.
One enzyme, several beds. Penis, coronary, pulmonary. Magnitude follows density and the clinical question you bother to ask. That is why Viagra, Revatio, and later class members can share a mechanism without sharing a dose card. Discovery is not proof that every bed answers equally.
Generic Viagra 50 mg is what most men still meet first. The brand diamond and the unbranded tablet carry the same citrate salt. The hold does not care about the imprint. Nitrates still win. Riociguat still wins. Arousal is still required.
I close this note the way I close the folder: planned target, unplanned winning tissue, leftover 50 mg start, later 20 mg TID product that must stay on its own shelf. Bring the spray list to your own clinician before anyone writes a first tablet. This desk does not fill.
Peer-line I still write for juniors: if an AE column keeps repeating an awkward sentence, read it twice before you archive the chemistry. Sandwich did not invent desire. It left a 50 mg tablet that only works when desire is already in the room. That is the whole discovery, minus the myth.
Reader mail
Reader questions on this article
Answered by Dr. Julian Frost, MD · Urology & men's sexual health
Margin questions on the angina file - I answer in the peer-line, not as your prescriber.
The enzyme was chosen on purpose. Angina was the planned cover. The accident was which tissue shouted loudest. Coronary change stayed small. Erectile change was obvious enough that someone reread the AE log instead of closing the file. I would not call the chemistry lucky. I would call the reading lucky. Without that reread, UK-92,480 dies like a hundred other thin cardiovascular leads. The 50 mg start we still write is the leftover of that reread, not a heart pill that 'also helps in bed.'
If it missed for the heart, why does a lung product exist?
Vasodilation was never nonsense. It was pointed at coronaries first. Pulmonary arteries carry PDE5 too, and PAH needs a steady drop in pulmonary resistance, not a one-hour peak. Revatio is 20 mg three times daily - a different product, different clinic, different endpoints. MedlinePlus keeps a plain PAH sketch at MedlinePlus. Do not split a 50 mg ED tablet to invent that schedule. Right-heart work is specialist work.
Will a 50 mg tablet give me an erection if I just sit there?
No. Sexual stimulation has to start the nitric oxide. The tablet holds the breakdown of cyclic GMP that arousal already made. No arousal, almost nothing to hold. Men who swallow 50 mg and wait for a spontaneous event decide the drug is dead. It is not dead. It is an amplifier. I write that on the first line of every new ED margin before I write the milligram.
I keep a nitrate spray for chest pain. Can I still use generic Viagra 50 mg?
No. Any organic nitrate or nitrite plus a PDE5 inhibitor is an absolute contraindication - profound hypotension, not a 'be careful' footnote. GTN spray, patches, isosorbide, recreational nitrites. The FDA states the prohibition on the FDA site. If chest pain arrives after a tablet, emergency care needs to know the timing. There is no tiny ED dose that makes the stack safe. Tell the clinician before anyone writes 25 or 50.
Why did approval wait until 1998 if men already reported erections?
An AE pattern is a clue, not a label. Regulators needed dedicated ED trials, validated questionnaires, dose-ranging, and safety across etiologies. That takes years. The pivot added a new program. It did not skip placebo-controlled evidence. IIEF and SEP datasets are what 1998 sat on - not the informal erection notes from the angina visits. I like the origin story. I will not let it replace the package.
Are Cialis and the later pills just copies of the same accident?
Same class insight, deliberate follow-on chemistry. Tadalafil was built for a long half-life and a daily option. Vardenafil sits closer to sildenafil on the clock and still minds a fatty plate. Nobody rediscovered the AE. They competed on duration, food, and schedule. If you want duration rather than origin, start with the tadalafil note. The nitrate hold is shared. The leftover 50 mg start is not.
Can I use leftover 50 mg tablets as if they were the lung product?
No. Same molecule, different product. Revatio 20 mg TID is specialist-managed PAH therapy with walk-distance and hemodynamic follow-up. ED tablets are on-demand 25, 50, or 100 mg, once daily. Splitting diamonds to approximate 20 mg TID is kitchen chemistry, not a label. If both problems live in one man, the PAH clinic and the urology desk need a shared plan. I will not write that plan from a thread.
Why does this site talk about 25 or 50 when the title says 50 mg?
Fifty milligrams is the usual labeled start and the SERP line on this page. Twenty-five is the other lock we keep for older men, hepatic or severe renal impairment, and strong CYP3A4 inhibitors. One hundred is a later step after a fair 50 mg trial, not the first word on the blotter. Site lock is 25 or 50. The ladder still exists in the body of the note. Titles are not the whole titration.
Did Sandwich 'invent' erections, or just notice them?
They invented a selective PDE5 blocker for a heart file. They noticed that the blocker was louder in erectile tissue than in coronaries. Noticing is the unglamorous half of discovery. Plenty of programs see an odd AE and code it away. This one changed the cover. I keep that as a method lesson, not a myth about a lucky blue pill falling out of a cupboard.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated